Which steroid is better and safer for skin problems: Prednisolone or Deflazacort? A comparative study in adults.

Balancing Efficacy and Safety: A prospective comparative study of Prednisolone and Deflazacort in adults with Steroid Responsive Dermatoses. - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/12/099122

Enrollment

Registered

2025-12-15

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L238- Allergic contact dermatitis due toother agents

Interventions

Intervention1: Prednisolone: Participants will receive Prednisolone orally in appropriate therapeutic doses depending on disease severity, tapered as clinically indicated. Intervention2: Deflazacort:

Eligibility

Inclusion criteria

Inclusion criteria: 1.Adults aged 18 65 years. 2.Clinically diagnosed with steroid-responsive dermatoses- Atopic Dermatitis, Allergic Contact Dermatitis, Irritant Contact Dermatitis, Lichen Planus, Discoid Lupus Erythematosus (DLE), Urticaria with Angioedema, Disseminated Eczema & Immunobullous disorders. 3.Requiring systemic corticosteroid therapy as per the treating dermatologist s decision. 4.Willing and able to provide written informed consent. 5.Willing to comply with study protocol and follow-up visits.

Exclusion criteria

Exclusion criteria: 1.Known hypersensitivity or contraindication to Prednisolone or Deflazacort. 2.Presence of uncontrolled diabetes mellitus, hypertension, peptic ulcer disease, or active infections (e.g., tuberculosis). 3.Current use of immunosuppressive agents other than corticosteroids. 4.Pregnant or lactating women. 5.History of psychiatric illness or substance abuse that may interfere with compliance. 6.Patients who have received systemic corticosteroids in the last 4 weeks. 7.Known hepatic or renal dysfunction, based on recent laboratory reports.

Design outcomes

Primary

Measure	Time frame
To compare the efficacy of Prednisolone and Deflazacort in the treatment of steroid-responsive dermatoses.Timepoint: participants will be evaluated at baseline and subsequently at 2-week intervals (Weeks 2, 4, 6, and 8) for a maximum duration of 3 months.	—

Secondary

Measure	Time frame
To evaluate and compare the frequency and severity of side effects associated with Prednisolone and Deflazacort therapy.Timepoint: participants will be evaluated at baseline and subsequently at 2-week intervals (Weeks 2, 4, 6, and 8) for a maximum duration of 3 months.	—

Countries

India

Contacts

Public ContactNadar Saundarya Chandrasekar

Chettinad Hospital and Research Institute

hod.dermatology@care.edu.in04447428101

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026